Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Selectikine||EMD 521873||Selectikine (EMD 521873) is composed of a DNA-targeted antibody linked to the cytokine IL-2, which potentially results in an increased anti-tumor immune response (PMID: 22918078, PMID: 25622640).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Selectikine||Phase I||Actionable||In a Phase I trial, Selectikine (EMD 521873) demonstrated safety and some preliminary activity in patients with advanced solid tumors (PMID: 22918078).||22918078|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|